Arrowhead (ARWR)
Biotech
Close on Nov 12, 2026 (from our latest Long View update): $47.15
- Market value
- $6.7Bat the Nov 12 close
- Revenue growth
- −46%12 months to Sep 30, 2026 (10-K)
- FCF margin
- −63%12 months to Sep 30, 2026 (10-K)
- Net cash
- $310Mat Sep 30, 2026
- Worst fall since listing
- −100.0%Dec 16, 1993 to Dec 16, 2016; not back to that high (−98.5% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
For most of its history Arrowhead funded itself by licensing drug candidates to larger companies, selling shares, selling future royalties and, from 2024, borrowing.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 12, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Arrowhead
Long-term fundamentals
Annual results for Arrowhead, FY2009–FY2026, as reported in its 10-K filings. Arrowhead's fiscal year ends in late September; FY2026 is the year that ended in September 2026.
Revenue and free cash flow
Revenue went from $0.3M in FY2011 to $451M in FY2026.
Free cash flow was positive in 3 of the 16 years shown; FY2026: −$284M.
Margins
Margins are not charted: in FY2026 the operating loss (−$707M) was larger than revenue ($451M). The table has each year's figures.
Diluted share count
The diluted share count rose 37% from FY2021 to FY2026, to 142M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2026 | $451M | — | −157% | −$724M | −$272M | $12M | −$284M |
| FY2025 | $829M | — | 12% | −$2M | $180M | $23M | $157M |
| FY2024 | $4M | — | −16927% | −$599M | −$463M | $141M | −$604M |
| FY2023 | $241M | — | −85% | −$205M | −$154M | $177M | −$331M |
| FY2022 | $243M | — | −73% | −$176M | −$136M | $53M | −$189M |
| FY2021 | $138M | — | −108% | −$141M | $171M | $24M | $148M |
| FY2020 | $88M | — | −106% | −$85M | −$96M | $12M | −$108M |
| FY2019 | $169M | — | 36% | $68M | $173M | $12M | $161M |
| FY2018 | $16M | — | −347% | −$54M | −$47M | $1M | −$49M |
| FY2017 | $31M | — | −118% | −$34M | −$24M | $8M | −$32M |
| FY2016 | $0.2M | — | −51627% | −$82M | −$64M | $4M | −$68M |
| FY2015 | $0.4M | — | −25124% | −$92M | −$66M | $2M | −$68M |
| FY2014 | $0.2M | — | −30444% | −$59M | −$35M | $2M | −$37M |
| FY2013 | $0.3M | — | −8471% | −$31M | −$19M | $0.3M | −$19M |
| FY2012 | $0.1M | — | −14359% | −$21M | −$15M | $0.5M | −$16M |
| FY2011 | $0.3M | — | −3319% | −$3M | −$8M | $0.0M | −$8M |
| FY2010 | — | — | — | −$6M | −$5M | — | — |
| FY2009 | — | — | — | −$19M | — | — | — |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2026 | 142M | $1.2B | $879M | $68M | — | — |
| FY2025 | 134M | $919M | $255M | $63M | — | — |
| FY2024 | 120M | $681M | $393M | $74M | — | — |
| FY2023 | 107M | $404M | $0 | $78M | — | — |
| FY2022 | 105M | $214M | — | $121M | — | — |
| FY2021 | 104M | $557M | — | $77M | — | — |
| FY2020 | 101M | $366M | — | $43M | — | — |
| FY2019 | 99M | $266M | — | $12M | — | — |
| FY2018 | 84M | $30M | $2M | $8M | — | — |
| FY2017 | 74M | $25M | $3M | $8M | — | — |
| FY2016 | — | $85M | $3M | $12M | — | — |
| FY2015 | — | $81M | — | $10M | — | — |
| FY2014 | — | $177M | $0.1M | $6M | — | — |
| FY2013 | — | $28M | $1M | $2M | — | — |
| FY2012 | — | $3M | $0.9M | $1M | — | — |
| FY2011 | — | $8M | $0.6M | $1M | — | — |
| FY2010 | — | $7M | $0.5M | $1M | — | — |
| FY2009 | — | $2M | — | $3M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 12, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- Diluted shares before FY2017 are left out: the earlier counts (before the company's listing or merger) are not comparable.
- FY2009 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- Cash for FY2022-2026 includes restricted cash (the only cash total tagged).
- Stock-based compensation for FY2009 is the amount recorded in equity (the cash-flow line is not tagged).
Returns by year
| Year | ARWR | S&P 500 |
|---|---|---|
| 2019 | +410.7% | +31.5% |
| 2020 | +21.0% | +18.4% |
| 2021 | −13.6% | +28.7% |
| 2022 | −38.8% | −18.1% |
| 2023 | −24.6% | +26.3% |
| 2024 | −38.6% | +25.0% |
| 2025 | +253.1% | +17.9% |
| 2026 to date | −34.3% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- KRYS Krystal Down 11%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- IOVA Iovance Down 35.4%
- TNGX Tango Therapeutics Down 16.4%
Show all 17
- SLS SELLAS Up 156.4%
- VKTX Viking Therapeutics
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- ALNY Alnylam
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- GMAB Genmab Up 28.3%
- ORIC ORIC Pharmaceuticals Down 32%
- MRNA Moderna Down 17.6%
Questions about Arrowhead
- How does Arrowhead make money?
- Almost all of its revenue still comes from partners that license its RNA-interference drug candidates and pay upfront fees, milestones and research reimbursements. Its first own drug, Redemplo (plozasiran), was approved in November 2025; product sales were $6.6M in the year to Sep 30, 2026, about 1.5% of revenue. More in the Long View →
- What is Redemplo?
- An RNAi medicine approved by the FDA on Nov 18, 2025 for familial chylomicronemia syndrome, a rare disease of very high triglycerides. Arrowhead sells it itself in the US through a specialty pharmacy; Sanofi sells it in China and pays Arrowhead royalties. More in the Long View →
- How does severe hypertriglyceridemia differ from Redemplo's approved indication?
- Severe hypertriglyceridemia affects a far larger patient population than familial chylomicronemia syndrome, Redemplo's approved indication. More in the Long View →
- How dependent is Arrowhead on partners?
- Almost all of its revenue has come from a few partners, and the largest has changed every few years as deals are signed. Sarepta and Novartis can end their agreements on 30 days' notice before a product is approved. More in the Long View →
- How does Arrowhead's borrowing constrain its strategy?
- Its $400M Sixth Street loan, refinanced on Nov 2, 2026, pays cash interest and is due in 2031. It requires at least $125M of cash in pledged US accounts and still restricts some asset sales and licensing deals, but it no longer takes a share of partner payments or product sales and allows more convertible debt. More in the Long View →
- What's coming up for Arrowhead's pipeline in the next 12 months?
- Arrowhead says it has submitted the plozasiran sNDA in severe hypertriglyceridemia, which qualifies for a 6-month priority review under the FDA's STAR pilot, and is preparing for a potential US launch in the second quarter of 2027. It anticipates that the Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia will be completed in mid-2027, and plans plozasiran sHTG submissions to other regulators in the future. As of Nov 12, 2026 More in the Long View →
Disclosure: one or more of our editors own shares of Arrowhead (ARWR) as a long-term investment.